tiero No Recession Today Doesn't Mean You Can Be Complacent To paraphrase Thomas Jefferson, "The price of financial liberty is eternal vigilance." Just because the economy today is good and not likely to get much worse in the future doesn't mean long-term investors can rest easily. Dividend Kings S&P Valuation Tool You never have to worry about the economy if you have an optimized long-term investment plan. Part of that plan is to select companies adaptable to changing economic and regulatory conditi ...

Dilok Klaisataporn 2024 Review The second half of 2024 kicks off on a bright note for the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) as the fund gained 5.15% in July. This brought the year-to-date return for the ETF up to 7.21% through the month-end of July. The SPDR S&P 500 ETF Trust (SPY) posted a gain of only 1.21% in July, however, year-to-date it is outpacing the aristocrats by a wide margin, up 16.62%. The trend from July has thus far extended into August. NOBL is up 2.63% through August 27th, ...

Abbott Laboratories (ABT) recently announced the expansion of its Pure Blissby Similacline of organic and European-made infant formulas. This line offers parents a variety of products to meet specific formula preferences.The expansion of Pure Bliss' line of products highlights Abbott’s motive to invest in clinical research and product development to advance nutrition science for babies of all ages.About Abbott’s Pure Bliss LinePure Bliss by Similac offers a range of organic or European-made infant formulas ...

Abbott’s (ABT) diversified business portfolio is well-positioned to drive continued momentum in 2024. However, Abbott is facing a challenging business environment globally. ABT currently carries a Zacks Rank #3 (Hold).Abbott continues to expand its Diagnostics business foothold (consisting of 21.2% of the total revenues in the second quarter of 2024). Over the past few quarters, the company has witnessed increased demand for routine diagnostics (excluding COVID-19 testing sales), particularly in the United ...

Core Insights - Abbott has expanded its Pure Bliss™ by Similac® line of organic and European-made infant formulas to meet diverse parental preferences for infant nutrition [1][2] Product Offerings - The Pure Bliss by Similac line includes: - Pure Bliss by Similac Irish Farms infant formula, made from fresh milk sourced from Irish farms, designed for easy digestion [2] - Pure Bliss by Similac Organic infant formula, a USDA-certified organic formula available in powder and liquid forms, noted for its convenience as the only USDA-certified organic liquid formula in select U.S. retail stores [2] - Pure Bliss by Similac Organic with A2 Milk infant formula, which uses milk from cows that produce A2 beta-casein protein, making it easier to digest and more similar to breast milk [2] Market Positioning - The expansion reflects a growing trend among parents seeking specific types of infant formulas, including organic, A2 milk, and ready-to-feed options [2] - Abbott's Pure Bliss line is backed by nearly a century of experience in providing high-quality infant nutrition inspired by breast milk [2][4] Availability - Pure Bliss by Similac products are available at major retailers such as Amazon, Target, and Walmart, with a product locator available on Similac's website for convenience [3] Commitment to Quality - Abbott emphasizes its commitment to quality and research in infant nutrition, offering a range of formulas that cater to various dietary needs and preferences [4]

Abbott Laboratories, Inc. (ABT) recently announced that the FDA has approved a change of label for its HeartMate 3 left ventricular assist device (LVAD or heart pump). The development, meant exclusively for patients with an Abbott HeartMate 3 heart pump, aims to provide superior clinical outcomes by eliminating aspirin as part of routine patient management.The labeling update is backed by the data from the company’s ARIES-HM3 trial and has also been approved by regulatory agencies in Canada and the European ...

These stocks pay above-average yields, and their dividend income could rise higher in the future.If you're buying a dividend stock, you need to carefully consider not just the payout ratio but also the company's long-term prospects. Intel suspended its dividend recently, an example of a situation that shouldn't have been all too surprising for a company that was struggling with profitability and growing its foundry business. In a situation like that, it's difficult to expect the company to invest in a costl ...

News paper headline Recession FearsgettyLet’s talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one. Here at Contrarian Outlook we have been preparing for slower economic readings, and our recession divvies have already delivered.Why the focus on slowdown safety? The Federal Reserve began hiking rates 2+ years ago. This is around the time something usually snaps in the financial markets. Sure enough, the Japanese yen o ...

After several quarters of margin-related hurdles, it seems Abbott (ABT) has finally combated this industry-wide challenge. The company’s second-quarter results reflected strong margin recovery, significantly raising investors’ optimism.Shares of this MedTech giant have risen 7.7% since its second-quarter earnings release on Jul 18 compared with the broader industry’s 3.2% increase. The stock has also outperformed the Medical sector’s 2% rise. The S&P 500, in contrast, declined 3.8% in this period.Abbott Out ...

An unexpected diabetes partnership with Medtronic bodes well for Abbott's biggest growth driver.According to a bullish Wall Street analyst, Abbott Laboratories (ABT -0.84%) stock could outperform for investors. Following the company's latest earnings report, Matt Miksic from Barclays maintained his buy rating and raised his price target to $143 per share.At recent prices, Miksic's price target predicts a gain of about 32% once the rest of the stock market sees Abbott Laboratories in the same light as he doe ...